重新思考如何在非裔美国男性中使用前列腺健康指数
本研究评估已验证的前列腺健康指数(PHI)风险分层在非裔美国(AA)男性中的表现,并尝试建立可排除前列腺活检需要的PHI阈值。209例符合FDA指征的AA男性中,91例(43.5%)检出临床显著前列腺癌(csPCa,Gleason评分≥7);PHI预测csPCa的AUC为0.68(95%CI:0.61-0.75)。以PHI<23.0避免活检的敏感性为98.9%、特异性为9.3%,仅可避免4.7%的活检;医师推荐后81.8%的患者接受了活检。作者认为PHI在本队列中表现有限,现行分层显示的癌症检出率偏低且可能误导,PHI在避免活检方面用途有限,仍需进一步研究评估和优化AA男性中PHI的使用,但其可能仍有助于提高活检推荐的依从性。
要点
- 在209例符合FDA指征的AA男性中,91例(43.5%)检出csPCa(Gleason评分≥7)。
- PHI预测csPCa的AUC为0.68(95%CI:0.61-0.75)。
- 以PHI<23.0避免活检的敏感性98.9%、特异性9.3%,仅可避免4.7%的活检。
核心结论
- PHI在本队列中表现有限,现行分层显示的癌症检出率偏低且可能误导。
- PHI在避免前列腺活检方面用途有限,所提出的阈值23.0仅使4.7%的男性避免活检。
- 仍需进一步研究评估和优化PHI在AA男性中的使用,但其可能仍有助于提高活检推荐的依从性。
研究设计与样本
- 纳入符合FDA规定的PHI检测指征(年龄>50岁、PSA 4-10、直肠指检阴性)并接受后续活检的AA男性。
- 记录按现行PHI分层划分的csPCa(Gleason评分≥7)发生率。
- 采用受试者工作特征曲线(ROC)分析评估PHI预测csPCa的表现,并确定提供90%敏感性的PHI切点。
- 在PSA 4-10 ng/mL的AA男性中,确定经医师推荐后接受活检者的比例。
主要发现
- 209例患者符合主要标准,其中91例(43.5%)检出csPCa。
- PHI预测csPCa的曲线下面积(AUC)为0.68(95%CI:0.61-0.75)。
- 以PHI阈值<23.0避免活检的敏感性为98.9%、特异性为9.3%,可避免4.7%的活检。
- 经医师推荐后接受活检者的比例为81.8%。
关键数值与推荐
- FDA规定的PHI检测指征:年龄>50岁、PSA 4-10、直肠指检阴性。
- csPCa定义为Gleason评分≥7。
- PHI预测csPCa的AUC为0.68(95%CI:0.61-0.75)。
- 以PHI<23.0避免活检:敏感性98.9%、特异性9.3%、可避免4.7%的活检。
- 经医师推荐后接受活检者的比例为81.8%。
临床怎么用
- 作者认为PHI在本队列中表现有限,现行分层显示的癌症检出率偏低且可能误导。
- 作者指出PHI在避免前列腺活检方面用途有限,所提出的阈值23.0仅使4.7%的男性避免活检。
- 作者认为仍需进一步研究评估和优化PHI在AA男性中的使用,但其可能仍有助于提高活检推荐的依从性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess how the validated Prostate Health Index (PHI) risk stratifications perform with African American (AA) men and establish a threshold PHI value to potentially rule out the need for prostate biopsy. MATERIALS AND METHODS: AA men meeting FDA-specified indications for PHI testing (>50 years old, PSA 4-10 and negative DRE) who underwent subsequent biopsy were included. Rates of clinically significant prostate cancer (csPCa, as defined by Gleason score ≥7) across accepted PHI stratifications were recorded. Receiver operator curve (ROC) analysis was undertaken to assess PHI performance to predict csPCa. A phi cutoff providing 90% sensitivity was identified. Among AA men with PSA 4-10 ng/mL, the proportion of men who proceeded to biopsy upon physician recommendation was determined. RESULTS: Two hundred nine patients met primary criteria; 91 (43.5%) of which had csPCA. The area under the curve for PHI predicting csPCa was 0.68 (95% CI: 0.61-0.75). Using a phi threshold of <23.0 to avoid biopsy provided 98.9% sensitivity, 9.3% specificity, and would have avoided 4.7% of biopsies. The proportion of those who proceeded to biopsy upon physician recommendation was 81.8%. CONCLUSIONS: PHI demonstrated limited performance in our cohort, with current stratifications featuring misleadingly low cancer detection rates for these men. Furthermore, PHI had limited use to avoid prostate biopsy, as the proposed threshold of 23.0 only allowed 4.7% of men to avoid biopsy. Further work is needed to assess and optimize PHI usage in AA men; nonetheless, it may still have use in increasing compliance with biopsy recommendation.
引用
- Morris KE, Kotamarti S, Polascik TJ, et al. Re-thinking How We Use Prostate Health Index for African American Men. Urology. 2023. PMID: 36828263. doi:10.1016/j.urology.2022.12.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。